Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Vertex Pharmaceuticals Inc (VRTX)  
$396.20 1.28 (0.32%) as of 4:30 Mon 4/29


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 260,040,000
Market Cap: 103.03(B)
Last Volume: 604,510 Avg Vol: 1,619,368
52 Week Range: $323.57 - $446.08
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     NASDAQ-100
    S&P 400 MIDCAP     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  543
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 67,740 152,280 258,193 599,211
Total Sell Value $28,555,052 $61,805,647 $99,413,137 $200,212,570
Total People Sold 8 12 15 18
Total Sell Transactions 28 41 68 132
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 3258
  Page 3 of 131  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Biller Jonathan EVP and Chief Legal Officer   •       –      –    2024-02-12 4 AS $418.77 $727,822 D/D (1,738) 18,280 -5%     
   Atkinson Edward Morrow Iii EVP, Chief Technical Ops. Off.   •       –      –    2024-02-12 4 AS $420.24 $383,679 D/D (913) 23,137 -5%     
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2024-02-12 4 AS $420.24 $131,955 D/D (314) 68,179 -5%     
   Altshuler David EVP, Global Research and CSO   •       –      –    2024-02-12 4 AS $420.24 $1,321,655 D/D (3,145) 47,588 -5%     
   Ambrose Kristen SVP & Chief Accounting Officer   •       –      –    2024-02-12 4 AS $420.24 $577,410 D/D (1,374) 9,676 -5%     
   Sachdev Amit EVP Chief Patient & Ext Af Off   •       –      –    2024-02-09 4 D $422.74 $854,780 D/D (2,022) 77,586     -
   Arbuckle Stuart A EVP, COO   •       –      –    2024-02-09 4 D $422.74 $1,343,045 D/D (3,177) 80,013     -
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2024-02-09 4 D $422.74 $1,102,083 D/D (2,607) 63,454     -
   Biller Jonathan EVP and Chief Legal Officer   •       –      –    2024-02-09 4 D $422.74 $671,311 D/D (1,588) 20,018     -
   Atkinson Edward Morrow Iii EVP, Chief Technical Ops. Off.   •       –      –    2024-02-09 4 D $422.74 $351,720 D/D (832) 24,050     -
   Bozic Carmen EVP and CMO   •       –      –    2024-02-09 4 D $422.74 $887,754 D/D (2,100) 46,810     -
   Kewalramani Reshma CEO & President   •       •      –    2024-02-09 4 D $422.74 $3,489,719 D/D (8,255) 162,271     -
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2024-02-09 4 D $422.74 $887,754 D/D (2,100) 68,493     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2024-02-09 4 D $422.74 $887,331 D/D (2,099) 50,733     -
   Ambrose Kristen SVP & Chief Accounting Officer   •       –      –    2024-02-09 4 D $422.74 $249,839 D/D (591) 11,050     -
   Leiden Jeffrey M Executive Chairman   •       •      –    2024-02-09 4 D $422.74 $3,402,212 D/D (8,048) 30,300     -
   Leiden Jeffrey M Executive Chairman   •       •      –    2024-02-08 4 D $421.73 $1,137,828 D/D (2,698) 38,348     -
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2024-02-07 4 A $0.00 $0 D/D 7,114 70,593     -
   Kewalramani Reshma CEO & President   •       •      –    2024-02-07 4 A $0.00 $0 D/D 20,327 170,526     -
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2024-02-07 4 A $0.00 $0 D/D 7,114 66,061     -
   Bozic Carmen EVP and CMO   •       –      –    2024-02-07 4 A $0.00 $0 D/D 5,928 48,910     -
   Sachdev Amit EVP Chief Patient & Ext Af Off   •       –      –    2024-02-07 4 A $0.00 $0 D/D 7,114 79,608     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2024-02-07 4 A $0.00 $0 D/D 7,114 52,832     -
   Arbuckle Stuart A EVP, COO   •       –      –    2024-02-07 4 A $0.00 $0 D/D 8,448 83,190     -
   Biller Jonathan EVP and Chief Legal Officer   •       –      –    2024-02-07 4 A $0.00 $0 D/D 4,743 21,606     -
  3258 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 3 of 131
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us